This CME-accredited activity, Wisconsin Multiple Myeloma & Lymphoma Summit, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia.

This activity aims to improve learners’ knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.


  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists


Hyatt Regency Milwaukee

A limited number of rooms have been reserved for the attendees of this conference at the Hyatt Regency Milwaukee at a discounted rate of $172 per night. Reserve your room at the following link by July 28th, 2023, to receive the discounted rate:


Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for induction and treatment for both transplant-eligible and transplant-ineligible with newly diagnosed multiple myeloma
  • Outline the management strategies for patients with 1-3 prior lines of therapy
  • Review indications and safety of CAR-T, bispecific antibodies MM, and lymphoma
  • Review the indications for the treatment of Waldenstrom Macroglobulinemia and current therapeutic strategies
  • Understand the evolving treatment strategies for the initial management of DLBCL